ACCG-3535 / Structure Therap - LARVOL DELTA

Oral Small Molecule Dual Amylin and Calcitonin Receptor Agonists (GlobeNewswire) - "(i) ACCG-2671...continues to be evaluated in an ongoing Phase 1 single ascending dose (SAD) clinical trial assessing safety, tolerability, pharmacokinetics and food effect in healthy adult participants. Initial data, along with initiation of a multiple ascending dose (MAD) clinical trial, remain on track for Q3 2026; (ii) The Company plans to initiate a Phase 1 clinical trial of its second oral small molecule dual amylin and calcitonin receptor agonist candidate, ACCG-3535, in Q4 2026, demonstrating continued leadership in the oral small molecule amylin field."

New P1 trial • P1 data • Obesity

Recent and Upcoming Milestones (GlobeNewswire) - "Initial data from the ongoing Phase 1 study of oral small molecule amylin receptor agonist ACCG-2671 and Phase 1 initiation of second oral amylin compound ACCG-3535 expected in 2H 2026...The Company expects to report topline results from the ACCESS II 44-week study in Q1 2026."

New P1 trial • P1 data • P2 data • Obesity

Oral Small Molecule Amylin Receptor Agonists for the Treatment of Obesity or Overweight with Comorbidities (GlobeNewswire) - "ACCG-2671 – Investigational new drug enabling activities for ACCG-2671 are ongoing, with the initiation of a first-in-human Phase 1 clinical study expected by year-end 2025....A second dual amylin and calcitonin receptor agonist development candidate, ACCG-3535, has been selected. ACCG-3535 is a unique chemical structure from ACCG-2671. Preclinical ACCG-3535 data were recently presented at Obesity Week 2025 demonstrating high binding affinity to human amylin and calcitonin receptors and balanced potency in human amylin and calcitonin receptor functional assays. In addition, ACCG-3535 demonstrated robust food intake suppression and significant, dose-dependent body weight reduction as a monotherapy in diet-induced obese rats."

New P1 trial • Preclinical • Obesity